| Zacks Company Profile for Ocugen, Inc. (OCGN : NSDQ) |
|
|
| |
| • Company Description |
| Ocugen Inc. is a clinical stage biopharmaceutical company. It is focused on discovering, developing and commercializing therapies which address rare and underserved eye diseases. The company's product pipeline consists of OCU400, OCU300, OCU100 and OCU200 which are in clinical stage. Ocugen Inc., formerly known as Histogenics Cp, is based in Malvern, Pennsylvania.
Number of Employees: 56 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $2.24 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 7,261,876 shares |
| Shares Outstanding: 215.66 (millions) |
| Market Capitalization: $483.08 (millions) |
| Beta: 4.59 |
| 52 Week High: $17.65 |
| 52 Week Low: $1.67 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
-8.94% |
2.56% |
| 12 Week |
-26.68% |
-19.39% |
| Year To Date |
-50.77% |
-39.85% |
|
|
|
|
| |
| • Address & Contact Information |
| Street Address |
Phone / Fax |
Email Address |
Web URL |
263 GREAT VALLEY PARKWAY SUITE 160
-
MALVERN,PA 19355
USA |
ph: 484-328-4701
fax: 781-547-4452 |
ir@ocugen.com |
http://ocugen.com |
|
|
| |
| • General Corporate Information |
Officers
Shankar Musunuri - Chief Executive Officer and Chairman
Sanjay Subramanian - Chief Financial Officer
Ramesh Kumar - Director
Junge Zhang - Director
Uday Kompella - Director
|
|
Peer Information
Ocugen, Inc. (CORR.)
Ocugen, Inc. (RSPI)
Ocugen, Inc. (CGXP)
Ocugen, Inc. (BGEN)
Ocugen, Inc. (GTBP)
Ocugen, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 67577C105
SIC: 2836
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/05/22
|
|
Share - Related Items
Shares Outstanding: 215.66
Most Recent Split Date: 9.00 (0.02:1)
Beta: 4.59
Market Capitalization: $483.08 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $-0.07 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $-0.30 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 3.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 08/05/22 |
|
|
|
| |
